Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Ask Therapept

Plain-English answers grounded in primary literature

Every answer is composed deterministically from verified scientific records, clinical trials, FDA labeling, and analytical lab data. No language model in the loop, zero synthetic hallucinations, and clear distinctions between human trials and animal models.

Popular questions with verified answers:
Medical Boundary:Therapept is an open-access scientific reference and educational catalog, not a clinic or medical provider. Answers are composed deterministically from verified database records, clinical trials, and FDA labeling. We never provide personal diagnoses, medical treatments, or individualized dosing instructions.
Question AnsweredDeterministic Attributed Record

what is retatrutide

1

Verified Source-Derived Information

Level 2 · Peer-Reviewed Phase 2 Interventional Clinical Trial·Reviewed: 2026-09-24
  • ✓Triple-agonist receptor profile targeting GLP-1R, GIPR, and GCGR (Glucagon).
  • ✓Phase 2 clinical trial (NEJM 2023, Jastreboff et al.) demonstrated up to 24.2% body weight loss at 48 weeks (12 mg dose, PMID 37364334).
  • ✓Investigational status: Currently in Phase 3 TRIUMPH trials; not approved by the FDA or EMA.
Attributed Sources:
2

Educational Explanation & Context

The Plain-English Summary

Retatrutide is an experimental triple-hormone peptide that set clinical trial records by reducing average body weight by up to 24.2% in Phase 2. It simultaneously activates three distinct metabolic receptors: GLP-1, GIP, and Glucagon.

Technical Mechanism & Details

Retatrutide (development code LY3437943) is a single 39-amino-acid peptide with an acylated C20 fatty diacid moiety that extends its plasma half-life to approximately 6 days, allowing once-weekly subcutaneous dosing. Its triple-agonist architecture coordinates satiety (GLP-1), improved insulin secretion and fat storage (GIP), and hepatic lipid clearance with thermogenesis (Glucagon).

Retatrutide was developed by Eli Lilly to explore whether adding a third hormone pathway (glucagon) could exceed the weight loss and glycemic control seen with single (GLP-1) or dual (GLP-1 + GIP) incretins.

In a landmark 48-week Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose (12 mg) lost an average of 24.2% of their body weight, compared to 2.1% in the placebo group.

3

Unknown / Not Available & Regulatory Boundaries

Retatrutide is in active Phase 3 evaluation (TRIUMPH). Complete long-term cardiovascular safety data remains pending final trial readouts.

Explicit Limitations & File Gaps:
  • •Retatrutide is NOT approved by the FDA for any therapeutic indication and is only available through clinical trials.

Helpful Follow-Up Questions

Related Guides & References on Therapept

How Ask Therapept Works: Deterministic Transparency

  • •Zero AI Hallucinations: Every answer is synthesized directly from verified database records, published peer-reviewed studies, FDA drug labels, and analytical chemistry testing guides. There is no generative language model fabricating unverified claims.
  • •Source Tier Transparency:Claims follow Therapept’s Level 1–5 evidence hierarchy — official FDA labeling, peer-reviewed research, editorial synthesis, and separated community signals.
  • •Honest Limits: Therapept will not provide personal medical advice, recommend unapproved dosages, or turn forum gossip into facts. When information is unstudied or restricted, Therapept states so clearly.